Table 1 Patient characteristics in both study groups and average dosages during run-in phase and treatment phase in both groups
From: Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial
Treatment Group | Methadone (METH) | LAAM | |
|---|---|---|---|
Total number (n) | 22 | 31 | |
Gender | 12 F/10 M | 11 F/20 M | |
Age (avg) | 31.0 yrs | 27.9 yrs | |
Average dosage during run-in period (METH in both groups) | 72.0 ± 25.5 mg daily | 73.5 ± 25.7 mg daily | |
Average dosage during treatment phase | 69 ± 27.6 mg METH | Mon & Wed | Fri |
89.6 ± 32.4 mg LAAM | 109.7 ± 39.5 mg LAAM | ||
equiv. to 68.9 ± 24.9 mg METH* | equiv. to 68.6 ± 24.7 mg METH* | ||